238 |
ALK RECEPTOR TYROSINE KINASE |
ALK |
CD246 |
NBLST3 |
105590 |
427 |
ENSG00000171094 |
OTTHUMG00000152034 |
ALK tyrosine kinase receptor |
CD_antigen=CD246 |
Anaplastic lymphoma kinase |
1839 |
NP_004295 |
Q9UM73 |
NM_004304 |
ALK_HUMAN |
ALK TYROSINE KINASE RECEPTOR PRECURSOR (EC 2.7.1.112) (ANAPLASTIC LYMPHOMA KINASE) (CD246 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UM73] |
1 |
PA24719 |
BE0000359 |
T56418 |
GuideToPharmacology Gene Category Name | Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family |
GuideToPharmacology Gene Category ID | 329 |
Interpro Acc | IPR001245 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Status | Swiss-Prot |
Human Readable Name | DRUGGABLE GENOME |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Uniprot Evidence | 1: Evidence at protein level |
Human Readable Name | KINASE |
Interpro Type | Domain |
CancerCommons Reported Gene Name | ALK, ROS |
CancerCommons Reported Gene Name | ALK |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
Gene Biotype | PROTEIN_CODING |
KINASE |
TYROSINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
inhibitor (inhibitory) |
Alteration | ALK:I1171T |
Drug family | ALK inhibitor |
Alteration | ALK__. |
inhibitor (inhibitory) |
Alteration | ALK:C1156Y,L1196M |
Alteration | ALK:L1198F |
Alteration | ALK:F856S,A348D |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Notes | |
Details of the Assay for Interaction | Result from DiscoveRx KINOMEscan® selectivity screen. |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Notes | |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | decreased response |
inhibitor (inhibitory) |
Approval Status | Preclinical - Cell line xenograft |
Response Type | conflicting |
Indication/Tumor Type | lung cancer |
inhibitor (inhibitory) |
Reported Cancer Type | Lung |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | resistant |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Wild type ALK |
Direct Interaction? | True |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Direct Interaction? | False |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Mechanism of Interaction | ALK tyrosine kinase receptor inhibitor |
Direct Interaction | yes |
n/a |
combination therapy | Crizotinib + Onalespib |
Indication/Tumor Type | non-small cell lung carcinoma |
Response Type | no benefit |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Details of Interaction | IC<sub>50</sub> for ALK<sup>G1202R</sup> is 1.2 nM. |
Endogenous Drug? | False |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
ALK | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
ALK | Gene Symbol |
Target Class | Receptors |
Target Subclass | EC:2.7.10.1 |
238 | Entrez Gene Id |
ALK_HUMAN | Uniprot Id |
Q9UM73 | Uniprot Accession |
Interpro Acc | IPR001245 |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Status | Swiss-Prot |
KINASE, DRUGGABLE GENOME |
238 | Entrez Gene ID |
CancerCommons Reported Gene Name | ALK, ROS |
CancerCommons Reported Gene Name | ALK |
ALK | Display Id |
ALK TYROSINE KINASE RECEPTOR PRECURSOR (EC 2.7.1.112) (ANAPLASTIC LYMPHOMA KINASE) (CD246 ANTIGEN). [SOURCE:UNIPROT/SWISSPROT;ACC:Q9UM73] | Description |
ENSG00000171094 | Ensembl Gene Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
427 | HUGO Gene ID |
427 | HUGO Gene Symbol |
ALK receptor tyrosine kinase | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family |
GuideToPharmacology Gene Category ID | 329 |
238 | CKB Entrez Id |
ALK | CKB Gene Synonym |
CD246 | CKB Gene Synonym |
PA24719 | PharmGKB ID |
238 | Entrez Gene ID |
1 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
ALK | DrugBank Gene Name |
Q9UM73 | UniProt Accession |
238 | Entrez Gene Id |
ALK | Gene Symbol |
ENSG00000171094 | Gene Symbol |
ALK | Ensembl Id |
DRUGGABLE GENOME |
238 | Entrez Gene Id |
ALK | MyCancerGenome Gene Symbol |
ALK | MyCancerGenome Reported Gene Name |
ALK | GENE_SYMBOL |
ALK tyrosine kinase receptor | UNIPROT |
Anaplastic lymphoma kinase | UNIPROT |
238 | OncoKB Entrez Id |
NBLST3 | OncoKB Gene Synonym |
CD246 | OncoKB Gene Synonym |
ALK tyrosine kinase receptor | Gene Name |
Q9UM73 | UniProt ID |
KINASE |
ALK | Gene Symbol |
CLINICALLY ACTIONABLE |
238 | Gene ID |
CD246 | dGene Synonym |
NBLST3 | dGene Synonym |
KINASE, TYROSINE KINASE |
ALK | TTD Gene Abbreviation |
T56418 | TTD Target ID |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
TYROSINE KINASE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |